Skip to content

Mirum Pharmaceuticals

US · MIRM #2051 by market cap Listed 2019
96.13 +0.62 +0.65%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 94.10 -1.48%
After-hours 96.13 0.00%
128.5779.2596.132026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MIRM?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +19.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 10.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 80.8% Better than 91%
Operating margin -4.2% Better than 17%
Net margin -4.5% Better than 20%
Return on equity -8.6% Better than 21%
Return on invested capital -3.8% Better than 23%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -0.2% Better than 73%
6-month return -2.5% Better than 51%
12-month return (ex latest month) 17.1% Better than 55%
Distance below 52-week high 26.1% Better than 49%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.7x Better than 69%
Debt to assets 37.9% Better than 30%
Interest coverage -0.5x Better than 23%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 65.2% Better than 74%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +2.28%
1M +13.00%
3M -0.97%
6M -0.85%
YTD +21.70%
1Y +39.00%
3Y +199.47%
5Y +512.68%

Key statistics

Price & volume

Prev close
95.51
Open
94.50
Day range
94.10 - 98.39
Avg price
96.96
Volume
1.06M
Turnover
103.00M
Amplitude
4.49%
52-week range
63.23 - 130.00

Valuation

P/E
-204.53
P/E (TTM)
-6.64
P/B
-115.82
EPS
-0.47
Net profit
-30.68M
Net assets
-54.18M

Share structure

Market cap
6.28B
Float cap
5.45B
Shares out
65.28M
Float shares
56.74M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-07-18
52-week range 49% of range
63.23 130.00

26.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-10.51M net over the window

Short interest

Shares short
6.52M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Mirum Pharmaceuticals (MIRM)?

Mirum Pharmaceuticals last traded at 96.13. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Mirum Pharmaceuticals's market cap?

About 6.28B.

What is the P/E ratio of Mirum Pharmaceuticals?

The trailing twelve-month P/E is -6.64. The Valuation tab shows it against the stock's own five-year range.

Does Mirum Pharmaceuticals pay a dividend?

Mirum Pharmaceuticals does not currently pay a regular dividend.

Is Mirum Pharmaceuticals a buy according to analysts?

The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 158.82, which implies 65.2% upside from the current price. This is not investment advice.

What is Mirum Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Mirum Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Mirum Pharmaceuticals discussion 0 comments

Add a comment